Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Treasury Shares: 2010-2025

Historic Treasury Shares for Vanda Pharmaceuticals (VNDA) over the last 14 years, with Sep 2025 value amounting to $3.5 million.

  • Vanda Pharmaceuticals' Treasury Shares rose 27.78% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year increase of 27.78%. This contributed to the annual value of $2.7 million for FY2024, which is 39.09% up from last year.
  • According to the latest figures from Q3 2025, Vanda Pharmaceuticals' Treasury Shares is $3.5 million, which was down 1.48% from $3.5 million recorded in Q2 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Treasury Shares peaked at $3.5 million during Q2 2025, and registered a low of $1.8 million during Q4 2021.
  • In the last 3 years, Vanda Pharmaceuticals' Treasury Shares had a median value of $2.7 million in 2024 and averaged $2.6 million.
  • Its Treasury Shares has fluctuated over the past 5 years, first dropped by 2.33% in 2023, then surged by 42.05% in 2024.
  • Vanda Pharmaceuticals' Treasury Shares (Quarterly) stood at $1.8 million in 2021, then climbed by 8.55% to $1.9 million in 2022, then fell by 0.53% to $1.9 million in 2023, then surged by 39.09% to $2.7 million in 2024, then climbed by 27.78% to $3.5 million in 2025.
  • Its last three reported values are $3.5 million in Q3 2025, $3.5 million for Q2 2025, and $3.3 million during Q1 2025.